| IVZ |
Report |
Adjusted diluted EPS |
BEAT |
pred ~$0.68 vs. cons ~$0.63 |
MEDIUM |
| IVZ |
Report |
Net revenues |
BEAT |
pred ~$1.34B vs. cons ~$1.30B |
MEDIUM |
| IVZ |
Report |
Adjusted operating margin |
BEAT |
pred ~37.5% vs. cons ~36.0% |
MEDIUM |
| IVZ |
Guide |
Q2 net long-term inflows (organic growth durability) |
BETTER |
guide ~$20B vs. cons ~$16B (Q2-26) |
MEDIUM |
| IVZ |
Guide |
FY26 adjusted operating expense framework |
UNCHANGED |
guide ~$3.275B vs. cons ~$3.28B (FY26) |
MEDIUM |
| IVZ |
Guide |
FY26 total capital-return payout ratio |
BETTER |
guide ~60% vs. cons ~55% (FY26) |
LOW |
| IVZ |
Guide |
QQQ fee/flow retention vs. new Nasdaq-100 competition |
UNKNOWN |
QQQ ~$490B AUM at 8bp license vs. cons flat-to-modest-leakage (H2-26) |
LOW |
| IVZ |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.8% |
— |
MEDIUM |
| IVZ |
Return |
5-day cumulative residual |
+2.0% (STABILIZE) |
Quarter's beat is largely mechanical since monthly AUM disclosures already telegraph ~7% higher average AUM, so the print is well anticipated and the stock has already rerated (+11.8% YTD, pressing YTD highs, beta ~1.73). A clean EPS/margin beat plus reassuring QQQ commentary supports a modest day-1 pop, but elevated expectations cap upside and invite partial sell-the-news. Out-period math is a wash: record ~$2.47T ending AUM lifts the Q3 revenue base (upward revisions), but the CI Financial ~$19B transfer drag in H2 and QQQ competitive/fee-leakage risk offset it, so estimates hold rather than ratchet — day-1 gain roughly stabilizes rather than follows through or fully fades. |
MEDIUM |